These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary). Cross G Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444 [TBL] [Abstract][Full Text] [Related]
5. API Global Sourcing Strategies 2010. Bennett S IDrugs; 2010 Sep; 13(9):605-6. PubMed ID: 20799139 [TBL] [Abstract][Full Text] [Related]
6. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 2. Kuhrt K IDrugs; 2009 Dec; 12(12):765-9. PubMed ID: 19943218 [TBL] [Abstract][Full Text] [Related]
7. The global impact of Indian generics on access to health. Ravinetto RM; Dorlo TP; Caudron JM; Prashanth NS Indian J Med Ethics; 2013; 10(2):118-20. PubMed ID: 23697493 [No Abstract] [Full Text] [Related]
8. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers. Falit BP; Singh SC; Brennan TA Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110 [TBL] [Abstract][Full Text] [Related]
9. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience. Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251 [TBL] [Abstract][Full Text] [Related]
10. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1. Kuhrt K; Chace-Ortiz M IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217 [TBL] [Abstract][Full Text] [Related]
11. Biosimilars in the United States: Emerging Issues in Litigation. Wong AY; Rumore MM; Chan AW BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972 [TBL] [Abstract][Full Text] [Related]
12. Business of Health. International Healthcare. Berry MD; Issue Brief Health Policy Track Serv; 2018 Dec; 2018():1-36. PubMed ID: 30681305 [No Abstract] [Full Text] [Related]
13. European Generic Medicines Association (EGA)--16th Annual Conference. Kennedy B IDrugs; 2010 Aug; 13(8):530-3. PubMed ID: 20721822 [TBL] [Abstract][Full Text] [Related]
14. Biosimilars and the long game. Huzair F; Kale D Trends Biotechnol; 2015 May; 33(5):250-2. PubMed ID: 25907144 [TBL] [Abstract][Full Text] [Related]
15. Biosimilars: Rationale and current regulatory landscape. Olech E Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438 [TBL] [Abstract][Full Text] [Related]
16. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude. Ehmann F; Papaluca Amati M; Salmonson T; Posch M; Vamvakas S; Hemmings R; Eichler HG; Schneider CK Clin Pharmacol Ther; 2013 May; 93(5):425-32. PubMed ID: 23549149 [TBL] [Abstract][Full Text] [Related]
17. European healthcare policies for controlling drug expenditure. Ess SM; Schneeweiss S; Szucs TD Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571 [TBL] [Abstract][Full Text] [Related]
18. Industry views of biosimilar development in Japan. Horikawa H; Tsubouchi M; Kawakami K Health Policy; 2009 Jul; 91(2):189-94. PubMed ID: 19157628 [TBL] [Abstract][Full Text] [Related]
20. If children ruled the pharmaceutical industry: the need for pediatric formulations. Rieder M Drug News Perspect; 2010 Sep; 23(7):458-64. PubMed ID: 20862398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]